Lupin Ltd Share Price

Lupin: Strong Global Growth & Pharma Momentum

Lupin delivered a strong start to FY27, with Q1 sales rising 33.3% YoY to ₹8,217 crore, EBITDA up 42.8% to ₹2,580 crore and PAT increasing 16% to ₹1,417 crore. US sales surged 42.9%, while India sales grew 13.9%, supported by strong formulation performance. Latest News: Other developed markets grew 48.3% and emerging markets 51.7%, showing broad-based international momentum. Lupin received 6 US FDA ANDA approvals and launched 3 products during the quarter. Corporate Action/Catalysts: Lupin has 50 First-to-File filings, including 21 exclusive opportunities, providing potential future US upside. Net cash stood at approximately ₹2,831 crore, giving the company financial flexibility. However, Citi recently downgraded Lupin to Sell with a ₹2,050 target, highlighting valuation concerns. Key risks include US pricing pressure, regulatory issues and high expectations after strong earnings growth.

See More

stocks Impulsive Move vs Corrective Move

any stock for example :

In technical analysis, understanding the difference between an impulsive move and a corrective move helps a trader identify whether the market is strongly moving in a direction or simply taking a temporary pause. An impulsive move is a strong and fast price movement in the direction of the main trend. In a bullish market, an impulsive move usually creates a Higher High (HH), while in a bearish market it creates a Lower Low (LL). These moves generally have strong candles, good momentum and often higher trading volume. For example, if a stock moves from ₹500 to ₹550 with strong candles and good volume, it shows that buyers are actively pushing the price higher. A corrective move is a temporary move against the main trend. After a strong rise, traders may book profits, causing the stock to fall for some time. This fall does not necessarily mean that the trend has changed. For example, if a stock moves from ₹500 to ₹600 and then falls to ₹570, the fall may simply be a correction. If the stock continues to hold its important support and later starts moving upward again, the main bullish trend is still intact. The easiest way to understand the market is: Impulse → Correction → Impulse → Correction During an impulsive move, candles are generally stronger and price moves quickly. During a correction, candles are usually smaller, price movement becomes slower and the market may look sideways or choppy. Market structure is the most important factor. In an uptrend, if price makes Higher Highs and Higher Lows, a normal pullback should ideally hold above the previous important Higher Low. If that level breaks strongly, the analyst needs to become cautious because the trend may be weakening. Volume and momentum can provide additional confirmation. Strong volume during a breakout supports an impulsive move, while lower volume during a pullback may indicate a normal correction.

See More

Lupin faces pressure as Citi turns bearish

shares came under pressure on August 27 after falling as much as 1.8% to a six-month low, before recovering most of the losses during afternoon trade. The stock was trading around ₹2,184, nearly flat from the previous close. The weakness followed Citi’s downgrade of Lupin to ‘Sell’, with the brokerage sharply cutting its target price to ₹2,050 from ₹2,540 earlier. Citi expects pressure on Lupin’s US business, pointing to weaker momentum in its base portfolio and limited visibility on replacing high-margin products such as generic Jynarque and generic Myrbetriq. The brokerage expects US sales to decline from around $1.3 billion in FY26 to $975 million by FY29, while EBITDA margins could fall from 30% in Q1 FY27 to around 20% by FY29. However, the negative view was partly offset by Bernstein, which retained its ‘Outperform’ rating with a ₹2,707 target. Bernstein highlighted Lupin’s recent patent win for generic Kalydeco (ivacaftor), which could allow an immediate launch in the US and provide 180 days of exclusivity. The contrasting brokerage views leave the stock at an important juncture, with investors likely to focus on the company’s US pipeline, product launches and ability to sustain margins.

See More

Lupin Ltd. Investment Update: Divergent Analyst Perspectives

Executive Summary Lupin Ltd. experienced a 2% decline in early trading on August 27, 2026, following a prominent downgrade. The stock, down approximately 9% YTD, currently presents a complex investment profile characterized by conflicting outlooks from major institutional brokerages. While Citi warns of structural headwinds and margin compression in the US market, Bernstein maintains a strong bullish stance driven by a recent patent litigation victory. Citi’s Bearish Thesis: Margin Compression & Pipeline Risks Citi has downgraded Lupin to ‘Sell,’ cutting its price target by 19% to ₹2,050. The downgrade is rooted in expected deceleration within Lupin's US operations: Revenue Contraction: US sales are projected to decline from ~$1.3 billion in FY26 to $975 million by FY29E. The current pipeline appears insufficient to offset the impending erosion of key high-margin products like gJynarque and gMyrbetriq. Margin Dilution: Consequently, EBITDA margins are forecasted to compress significantly, falling from 30% in Q1FY27 to 20% by FY29E. Execution Risk: While Apixaban may offer temporary earnings support in FY28E, long-term growth drivers (Neulasta Onpro, Etanercept, and Spiriva Respimat) remain unfiled. This severely limits near-term visibility and elevates execution risk. Bernstein’s Bullish Thesis: Kalydeco Litigation Victory In stark contrast, Bernstein reiterates an ‘Outperform’ rating with a ₹2,707 price target, focusing on a critical legal catalyst. Commercial Catalyst: This judgment removes the primary barrier for Lupin’s first-to-file program. The drug, which treats cystic fibrosis, already holds tentative US FDA approval and carries 180 days of lucrative market exclusivity. Financial Impact: Bernstein estimates this product will contribute $20–$30 million in annual sales, adding up to 2.1% to Lupin's current annualized US revenue base.

See More

Lupin - A failed Rounding bottom Breakout - Trapped Investor

is showing a failed breakout setup on the daily chart after briefly moving above the important ₹2,420 resistance zone but failing to sustain the breakout. The stock extended its move toward ₹2,500–2,520 before facing sharp profit booking, and the subsequent decline back below ₹2,420 has weakened the bullish structure. This rejection indicates that the previous resistance has once again acted as a strong supply zone, with breakout buyers now facing pressure. The immediate support is around ₹2,180–2,200, while a sustained break below this zone could extend the correction toward ₹2,100 and ₹2,025. On the upside, ₹2,420 is now the key level to reclaim; only a decisive close above this resistance, preferably with strong follow-through, would restore the breakout setup and reopen the path toward ₹2,500 and higher levels. Until then, the failed breakout warrants caution, as momentum has shifted from bullish to corrective after the rejection from the ₹2,500 zone.

See More